These two authors contributed equally to this work.
Hydroxychavicol, a Piper betle leaf component, induces apoptosis of CML cells through mitochondrial reactive oxygen species-dependent JNK and endothelial nitric oxide synthase activation and overrides imatinib resistance
Article first published online: 7 NOV 2011
© 2011 Japanese Cancer Association
Volume 103, Issue 1, pages 88–99, January 2012
How to Cite
Chakraborty, J. B., Mahato, S. K., Joshi, K., Shinde, V., Rakshit, S., Biswas, N., Choudhury (Mukherjee), I., Mandal, L., Ganguly, D., Chowdhury, A. A., Chaudhuri, J., Paul, K., Pal, B. C., Vinayagam, J., Pal, C., Manna, A., Jaisankar, P., Chaudhuri, U., Konar, A., Roy, S. and Bandyopadhyay, S. (2012), Hydroxychavicol, a Piper betle leaf component, induces apoptosis of CML cells through mitochondrial reactive oxygen species-dependent JNK and endothelial nitric oxide synthase activation and overrides imatinib resistance. Cancer Science, 103: 88–99. doi: 10.1111/j.1349-7006.2011.02107.x
- Issue published online: 6 JAN 2012
- Article first published online: 7 NOV 2011
- Accepted manuscript online: 22 SEP 2011 08:48AM EST
- (Received July 13, 2011/Revised September 13, 2011/Accepted September 15, 2011/Accepted manuscript online September 22, 2011/Article first published online November 8, 2011)
Fig. S1. Hydroxychavicol (HCH)-induced reactive oxygen species (ROS) originates from mitochondria.
Fig. S2. Pretreatment with diethyldithiocarbamate (DETC) (50 mM) enhances the accumulation of superoxide but lowers the level of H2O2 while pretreatment with aminotriazole (ATZ) (2.0 mM) enhances the accumulation of H2O2 after treatment of K562 cells with HCH (5.0 mg/mL).
Fig. S3. Hydroxychavicol (HCH) does not interact with N-acetylcysteine (NAC).
Fig. S4. Hydroxychavicol (HCH) treatment does not deplete intracellular glutathione.
Fig. S5. Contribution of JNK in hydroxychavicol (HCH)-induced nitric oxide (NO) production and apoptosis in K562 cells.
Fig. S6. Relative body weight profile of SCID mice bearing SCID mice bearing Ba/F3Bcr-Abl P210wild type or Ba/F3 T3151 Bcr-Abl P210T315I xenografts after oral administration of vehicle control or ICB3E twice daily for 10 days.
Data S1. xxx.
|CAS_2107_sm_DataS1.doc||226K||Supporting info item|
|CAS_2107_sm_f2.jpg||271K||Supporting info item|
|CAS_2107_sm_f3.jpg||438K||Supporting info item|
|CAS_2107_sm_f4.jpg||389K||Supporting info item|
|CAS_2107_sm_f5.jpg||807K||Supporting info item|
|CAS_2107_sm_f6.jpg||324K||Supporting info item|
|CAS_2107_sm_fS1.jpg||430K||Supporting info item|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.